54741_Image_jpeg.jpg
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 06, 2022 08:00 ET | Daxor Corporation
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh...
54741_Image_jpeg.jpg
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
September 14, 2021 08:30 ET | Daxor Corporation
Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing...
54741_Image_jpeg.jpg
Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021
August 30, 2021 08:30 ET | Daxor Corporation
Company forecasts further increase in sales driven by new distributor agreements Oak Ridge, TN, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
May 13, 2021 08:30 ET | Daxor Corporation
NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in...
54741_Image_jpeg.jpg
Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs
May 06, 2021 08:30 ET | Daxor Corporation
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical...
54741_Image_jpeg.jpg
DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE
March 18, 2021 08:30 ET | Daxor Corporation
NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
54741_Image_jpeg.jpg
Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:30 ET | Daxor Corporation
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
54741_Image_jpeg.jpg
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
February 19, 2021 08:30 ET | Daxor Corporation
Important Milestone for International Distribution NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces...
54741_Image_jpeg.jpg
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
February 05, 2021 08:30 ET | Daxor Corporation
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the...
54741_Image_jpeg.jpg
DAXOR CORPORATION TO EXHIBIT AT THE SOCIETY FOR CRITICAL CARE MEDICINE 50TH CONGRESS VIRTUAL EVENT
January 26, 2021 08:30 ET | Daxor Corporation
NEW DATA SCHEDULED FOR PRESENTATION ON DAXOR’S BVA-100® BLOOD TEST NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement...